Pivotal trial results for secukinumab (Cosentyx) in patients with active psoriatic arthritis were published on 2015-01-01. The FUTURE 2 study demonstrated efficacy at 24 weeks, alongside long-term safety, tolerability, and efficacy extending up to 5 years.
Background
Secukinumab is a human anti-interleukin-17A monoclonal antibody. It was investigated for the treatment of psoriatic arthritis, a chronic inflammatory disease affecting joints and skin.
Trial design
The FUTURE 2 study was a randomised, double-blind, placebo-controlled trial. It evaluated secukinumab in patients with active psoriatic arthritis.
Key results
The study demonstrated efficacy at 24 weeks. Furthermore, the trial assessed long-term safety, tolerability, and efficacy of secukinumab, with observations extending up to 5 years in patients with active psoriatic arthritis.
What this means
The publication of the FUTURE 2 pivotal trial results provides important evidence regarding the clinical profile of secukinumab for patients with active psoriatic arthritis. The demonstration of efficacy at 24 weeks, combined with long-term safety, tolerability, and sustained efficacy over 5 years, supports its potential role in managing this condition.
Source
The information regarding these pivotal trial results was obtained from PubMed. The publication, titled 'Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled,' was published on 2015-01-01 and is available on pubmed.ncbi.nlm.nih.gov.